Physiomics wins prostate cancer drug deal
13th Sep 2011 09:22
Physiomics, which makes computer models that simulate biological cell behaviour, has agreed to collaborate over development of a prostate cancer drug. The agreement with ValiPharam Limited will see Physiomics help test how the drug "VAL201" performs in combating tumour growth. In essence Physionom
Read moreLondon midday: FTSE 100 stable after calm start
15th Aug 2011 12:21
Shares are holding onto their gains today amid much calmer trading than the volatility seen last week. In company news, international recruitment firm Michael Page is sharply lower. It made a flying start to 2011 but said profit growth in the banking sector has tailed off in the second half of the
Read moreCancer results boost Sareum
15th Aug 2011 11:50
Cancer drug discovery business Sareum shot ahead after it said it had selected a "preclinical development candidate" from research into Chk1, a method of controlling a cancer cells' response to DNA damage. The candidate, when orally dosed, reduces cancer growth rates compared to treatment with the
Read morePhysiomics issues shares at discount
6th Apr 2011 15:13
Penny stock Physiomics fell sharply Wednesday, giving back some of last week's heavy gains, after announcing a share issue at a discount to the prevailing market price. The company has issued 120m shares at a price of 0.5p per share by way of a placing, to raise £0.6m to boost working capital. Fo
Read morePhysiomics hits 52-week high on study outcome
1st Apr 2011 16:11
The Oxford based systems biology company Physiomics said positive results have been generated in a pre-clinical study into breast cancer based on the company's "Virtual Tumour" model predictions. The directors believe these results provide further validation as to the predictive capability of the
Read moreSareum soars after colon cancer study
4th Mar 2011 11:08
Shares in Sareum were soaring after the cancer drug discovery business announced positive results from a study into colon cancer. The study, which was conducted by the Institute of Cancer Research, founded that Sareum's Chk1 inhibitor, used alongside a gemcitabine, a chemotherapeutic, "demonstrate
Read moreLondon close: Late rally not enough
15th Feb 2011 16:44
Weakness in the US sent shares into the red and a slight rally in late trading failed to lift the FTSE 100 into positive territory. US retail sales were up 0.3% in January, according to the Commerce Department, though they'd risen 0.5% the month before and were expected to do the same this time. Ex
Read moreSmall caps round-up: Amphion, Bioquell, Ablon...
16th Mar 2010 10:50
Shares in Amphion Innovations jumped after the medical and technology sector said it was cautious but confident in the strength of its model following a year which saw revenue increase to $8.6m from $7.1m in 2008, but losses increase to $2.9m from $1.8m. Shares in Bioquell moved in the other direct
Read moreSmall caps round-up: Beowulf, E2V, Mobile Doctors...
1st Mar 2010 11:04
Beowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren
Read moreSmall caps round-up: Veris, Hightex, Inion ...
23rd Jun 2009 09:04
Property services group Veris posted a pre-tax loss of €6.7m versus the €4.8m profit last year due to the €11.3m write off of assts in the Moving and Storage division. Turnover grew by 29% in the year to €84.3m. "We anticipate that any new business wins in the short term will be offset to a greater
Read more